180 Life Sciences Corp. (ATNF)
Market Cap | 79.39M |
Revenue (ttm) | n/a |
Net Income (ttm) | -4.70M |
Shares Out | 5.18M |
EPS (ttm) | -36.61 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 22 |
Last Price | $3.88 |
Previous Close | $3.49 |
Change ($) | 0.39 |
Change (%) | 11.17% |
Day's Open | 3.45 |
Day's Range | 3.38 - 4.18 |
Day's Volume | 3,998,304 |
52-Week Range | 2.15 - 11.24 |
Menlo Park, California--(Newsfile Corp. - January 11, 2021) - 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead ...
NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire ...
Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp...
NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire ...
KBL Merger Corp. IV (NASDAQ: KBLM) on Friday announced its acquisition of a new cannabis biotech company CannBioRx Life Sciences Corp.
About ATNF
180 Life Sciences, a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California... [Read more...]
Industry Biotechnology | Founded 2016 |
Stock Exchange NASDAQ | Ticker Symbol ATNF |